VeriMomSollte ich methyl bimatoprost acidate in der Schwangerschaft meiden? | VeriMom
H361 (‘suspected of damaging fertility or the unborn child’) is reported for this substance in supplier/EU SDS/C&L‑type entries and the SCCS included methyl bimatoprost acidate among prostaglandin analogues of concern for cosmetic use; animal reproductive studies with bimatoprost show abortion, increased resorptions and post‑natal pup effects at high doses, and the Latisse/Lumigan product label advises caution in pregnancy. These facts support h=2 (suspected). Mechanistically, prostaglandin analogues have demonstrated reproductive/developmental effects in animal studies (m=2). Systemic absorption from topical/ocular application is low but measurable, so exposure from cosmetic topical use is low but real (e=1). Sources: SCCS opinion, FDA/LATISSE label, supplier SDS.
ECHA regulatory hazard statements
- •H361
- •H362
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- Ist methyl bimatoprost acidate in der Schwangerschaft sicher?
- H361 (‘suspected of damaging fertility or the unborn child’) is reported for this substance in supplier/EU SDS/C&L‑type entries and the SCCS included methyl bimatoprost acidate among prostaglandin analogues of concern for cosmetic use; animal reproductive studies with bimatoprost show abortion, increased resorptions and post‑natal pup effects at high doses, and the Latisse/Lumigan product label advises caution in pregnancy. These facts support h=2 (suspected). Mechanistically, prostaglandin analogues have demonstrated reproductive/developmental effects in animal studies (m=2). Systemic absorption from topical/ocular application is low but measurable, so exposure from cosmetic topical use is low but real (e=1). Sources: SCCS opinion, FDA/LATISSE label, supplier SDS.
- Ist methyl bimatoprost acidate während des Stillens sicher?
- Supplier safety data and regulatory/product labels record H362 (may cause harm to breast‑fed children) and state bimatoprost is excreted in milk in animal studies. Given the parent drug is excreted in milk (per product labels) and the substance is classed with H362 in SDSs, h=2 is appropriate. Mechanism evidence (excretion into milk, documented neonatal effects in animal studies) supports m=2. Exposure by topical cosmetic use is low but measurable (e=1). Sources: FDA/LATISSE label, supplier SDSs.
- Ist methyl bimatoprost acidate sicher für Babyhaut?
- Do not increase hazard (h) or mechanism (m) absent infant‑specific data; retain h=2 and m=2 because the substance is a prostaglandin analogue with suspected reproductive/lactation hazards. Increase exposure (e) by +1 for baby skin per instructions because infant skin is more permeable and systemic exposure from topical application is measurable — therefore e=2 for 0–3‑year‑old skin. Sources: SCCS opinion, FDA product label, supplier SDSs.
- Wie bewertet VeriMom methyl bimatoprost acidate?
- VeriMom bewertet methyl bimatoprost acidate mit 20/100 (hohes Risiko) basierend auf EU CosIng, ECHA-Klassifizierungen und PubMed-Studien.
- Was sind schwangerschaftssichere Alternativen zu methyl bimatoprost acidate?
- Siehe unsere kuratierte Liste der schwangerschaftssicheren Alternativen zu methyl bimatoprost acidate basierend auf ähnlicher Funktion.
Prüfe jede Zutatenliste in 2 Sekunden
Lade VeriMom kostenlos — scanne jedes Produkt und sieh sofort die Schwangerschafts-Sicherheitsbewertung.
Medizinischer Haftungsausschluss
Diese Informationen dienen ausschließlich Bildungszwecken und stellen keine medizinische Beratung dar. Sicherheitsbewertungen basieren auf öffentlich zugänglichen Daten und spiegeln möglicherweise nicht alle Risiken wider. Konsultieren Sie immer Ihren Arzt, bevor Sie ein Produkt während der Schwangerschaft oder Stillzeit verwenden.